Hoth Therapeutics (HOTH) Competitors $0.86 -0.04 (-4.78%) As of 12:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. CNTB, ITRM, ATRA, FBLG, IPSC, VRCA, TNYA, BLUE, RVPH, and XLOShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Connect Biopharma (CNTB), Iterum Therapeutics (ITRM), Atara Biotherapeutics (ATRA), FibroBiologics (FBLG), Century Therapeutics (IPSC), Verrica Pharmaceuticals (VRCA), Tenaya Therapeutics (TNYA), bluebird bio (BLUE), Reviva Pharmaceuticals (RVPH), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Connect Biopharma Iterum Therapeutics Atara Biotherapeutics FibroBiologics Century Therapeutics Verrica Pharmaceuticals Tenaya Therapeutics bluebird bio Reviva Pharmaceuticals Xilio Therapeutics Hoth Therapeutics (NASDAQ:HOTH) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Does the media refer more to HOTH or CNTB? In the previous week, Hoth Therapeutics had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for Hoth Therapeutics and 2 mentions for Connect Biopharma. Hoth Therapeutics' average media sentiment score of 0.72 beat Connect Biopharma's score of 0.30 indicating that Hoth Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Hoth Therapeutics Positive Connect Biopharma Neutral Which has more risk and volatility, HOTH or CNTB? Hoth Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.22, indicating that its stock price is 122% less volatile than the S&P 500. Does the MarketBeat Community favor HOTH or CNTB? Hoth Therapeutics received 59 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 73.08% of users gave Connect Biopharma an outperform vote while only 67.24% of users gave Hoth Therapeutics an outperform vote. CompanyUnderperformOutperformHoth TherapeuticsOutperform Votes7867.24% Underperform Votes3832.76% Connect BiopharmaOutperform Votes1973.08% Underperform Votes726.92% Is HOTH or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -89.68% -82.61% Connect Biopharma N/A N/A N/A Which has preferable earnings & valuation, HOTH or CNTB? Hoth Therapeutics has higher earnings, but lower revenue than Connect Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$7.84M-$1.33-0.64Connect Biopharma$24.12M1.92-$59.50MN/AN/A Do institutionals & insiders hold more shares of HOTH or CNTB? 7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 10.6% of Hoth Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer HOTH or CNTB? Hoth Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 367.29%. Connect Biopharma has a consensus target price of $8.00, suggesting a potential upside of 855.79%. Given Connect Biopharma's higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHoth Therapeutics beats Connect Biopharma on 8 of the 15 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.27M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.657.3622.6118.58Price / SalesN/A241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book0.426.486.704.26Net Income-$7.84M$143.43M$3.22B$248.31M7 Day Performance-0.31%1.69%1.26%1.34%1 Month Performance-12.18%6.58%3.73%3.92%1 Year Performance-29.84%-2.63%15.82%5.33% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics3.1687 of 5 stars$0.86-4.8%$4.00+367.3%-26.3%$11.27MN/A-0.654Short Interest ↓CNTBConnect Biopharma2.5974 of 5 stars$0.81+3.7%$8.00+887.7%-40.9%$44.83M$24.12M0.00110Gap UpITRMIterum Therapeutics2.5131 of 5 stars$1.26flat$5.00+296.8%-26.8%$43.57MN/A-0.9610Short Interest ↓News CoverageATRAAtara Biotherapeutics4.0411 of 5 stars$7.42+1.4%$17.75+139.2%-53.7%$43.47M$128.94M-0.29330Upcoming EarningsPositive NewsFBLGFibroBiologics2.6795 of 5 stars$1.14-7.0%$13.00+1,045.4%-88.1%$42.83MN/A-3.3410Short Interest ↓IPSCCentury Therapeutics1.9863 of 5 stars$0.50-0.8%$4.40+784.2%-81.4%$42.82M$6.59M-0.27170Upcoming EarningsNews CoverageVRCAVerrica Pharmaceuticals4.1529 of 5 stars$0.46-5.1%$9.50+1,947.0%-93.3%$42.60M$7.57M-0.2540Gap UpTNYATenaya Therapeutics3.7929 of 5 stars$0.48-1.5%$6.25+1,191.9%-89.5%$42.37MN/A-0.34110Short Interest ↓BLUEbluebird bio3.0006 of 5 stars$4.19+0.7%$44.60+964.4%-77.0%$41.02M$83.81M-0.11520Upcoming EarningsAnalyst ForecastRVPHReviva Pharmaceuticals2.797 of 5 stars$0.87+1.8%$10.00+1,048.9%-70.9%$40.68MN/A-0.785Short Interest ↑XLOXilio Therapeutics3.513 of 5 stars$0.79-5.2%$4.00+409.4%-26.4%$40.65M$6.34M-0.4670Positive News Related Companies and Tools Related Companies Connect Biopharma Alternatives Iterum Therapeutics Alternatives Atara Biotherapeutics Alternatives FibroBiologics Alternatives Century Therapeutics Alternatives Verrica Pharmaceuticals Alternatives Tenaya Therapeutics Alternatives bluebird bio Alternatives Reviva Pharmaceuticals Alternatives Xilio Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOTH Stock Free HOTH Stock Alerts